NCT00724230View on ClinicalTrials.gov

Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)

CompletedOBSERVATIONAL

Enrollment

505

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Hepatitis C, ChronicHepatitis C

Interventions

DRUG

PegIntron (peginterferon alfa-2b; SCH 54031)

"PegIntron administered in accordance with approved labeling~Subcutaneous injection once weekly for 24 weeks."

DRUG

Rebetol (ribavirin; SCH 18908)

Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00724230 - Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED) | Biotech Hunter | Biotech Hunter